Placental growth factor (PGF) is member of the vascular endothelial growth factor (VEGF) family of angiogenesis regulators. VEGFA is an established regulator of ovulation and formation of the corpus luteum. To determine whether PGF also mediates aspects of ovulation and luteinization, macaques received gonadotropins to stimulate multiple follicular development. Ovarian biopsies and whole ovaries were collected before (0 hours) and up to 36 hours after human chorionic gonadotropin (hCG) administration to span the ovulatory interval. PGF and VEGFA were expressed by both granulosa cells and theca cells. In follicular fluid, PGF and VEGFA levels were lowest before hCG. PGF levels remained low until 36 hours after hCG administration, when PGF increased sevenfold to reach peak levels. Follicular fluid VEGFA increased threefold to reach peak levels at 12 hours after hCG, then dropped to intermediate levels. To explore the roles of PGF and VEGFA in ovulation, luteinization, and follicular angiogenesis in vivo, antibodies were injected into the follicular fluid of naturally developed monkey follicles; ovariectomy was performed 48 hours after hCG, with ovulation expected about 40 hours after hCG. Intrafollicular injection of control immunoglobulin G resulted in no retained oocytes, follicle rupture, and structural luteinization, including granulosa cell hypertrophy and capillary formation in the granulosa cell layer. PGF antibody injection resulted in oocyte retention, abnormal rupture, and incomplete luteinization, with limited and disorganized angiogenesis. Injection of a VEGFA antibody resulted in oocyte retention and very limited follicle rupture or structural luteinization. These studies demonstrate that PGF, in addition to VEGFA, is required for ovulation, luteinization, and follicular angiogenesis in primates.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774250 | PMC |
http://dx.doi.org/10.1210/en.2017-00739 | DOI Listing |
JMIR Form Res
January 2025
Klick Applied Sciences, Klick Health, Toronto, ON, Canada.
Background: Identifying subtle changes in the menstrual cycle is crucial for effective fertility tracking and understanding reproductive health.
Objective: The aim of the study is to explore how fundamental frequency features vary between menstrual phases using daily voice recordings.
Methods: This study analyzed smartphone-collected voice recordings from 16 naturally cycling female participants, collected every day for 1 full menstrual cycle.
Toxicol Res (Camb)
January 2025
Department of Obstetrics and Gynecology, Jinggangshan University Clinical School of Medicine, No. 28 Xueyuan Road, Ji'an, Jiangxi 343000, China.
Ovarian cancer (OC) is a significant cause of cancer-related mortality among women. This study explores the efficacy of L. () extract, known for its phytoestrogenic properties, in treating OC through hormonal and metabolic modulation.
View Article and Find Full Text PDFJ Assist Reprod Genet
January 2025
Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences, School of Basic Medicine, Center of Excellence in Tissue Engineering of Chinese Academy of Medical Sciences, Peking Union Medical College, Peking Union Medical College Hospital, Beijing Key Laboratory, PekingBeijing, 100730, China.
Background: Luteinizing hormone (LH) plays a crucial role in the postnatal development and maturation of gonads. Inactivating mutations of the luteinizing hormone beta subunit (LHB)gene are extremely rare and can result in congenital hypogonadotropic hypogonadism (CHH).
Methods: We conducted DNA sequencing on an 18-year-old female patient with undetectable LH and clinical symptoms of CHH.
Cochrane Database Syst Rev
January 2025
Institute of Education in Healthcare and Medical Sciences, University of Aberdeen, Aberdeen, UK.
Background: Gonadotropin-releasing hormone agonists (GnRHa) are commonly used in assisted reproduction technology (ART) cycles to prevent a luteinising hormone (LH) surge during controlled ovarian hyperstimulation (COH) prior to planned oocyte retrieval, thus optimising the chances of live birth. We compared the benefits and risks of the different GnRHa protocols used.
Objectives: To evaluate the effectiveness and safety of different GnRHa protocols used as adjuncts to COH in women undergoing ART.
F S Rep
December 2024
Department of Obstetrics and Gynaecology, University of Ottawa, Ottawa, Ontario, Canada.
Objective: To report a patient with McCune-Albright syndrome (MAS) with bilateral ovarian involvement who had achieved a pregnancy through in vitro fertilization (IVF).
Design: Case report.
Setting: Academic fertility center.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!